Stryker (NYSE:SYK – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 13.450-13.700 for the period, compared to the consensus EPS estimate of 13.510. The company issued revenue guidance of -.
Stryker Stock Performance
NYSE SYK opened at $394.92 on Wednesday. The company has a market cap of $150.55 billion, a PE ratio of 42.33, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95. The stock’s 50 day simple moving average is $376.44 and its 200-day simple moving average is $361.98. Stryker has a 1-year low of $310.74 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same period last year, the company posted $3.46 EPS. As a group, equities research analysts anticipate that Stryker will post 12.06 EPS for the current fiscal year.
Stryker Increases Dividend
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on SYK shares. Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Piper Sandler reissued an “overweight” rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, Robert W. Baird boosted their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $411.30.
Get Our Latest Stock Report on SYK
Insider Activity at Stryker
In related news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
- Five stocks we like better than Stryker
- Retail Stocks Investing, Explained
- 3 Steel Stocks Soaring After Tariff Announcements
- The 3 Best Blue-Chip Stocks to Buy Now
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- What is a Secondary Public Offering? What Investors Need to Know
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.